Korea JoongAng Daily

@koreajoongangdaily.com

1 week ago

Celltrion chairman says firm safe from global instability at shareholder meeting Seo Jung-jin, chairman of Celltrion Group, returned as chair of the biopharmaceutical's general shareholder meeting for the first time in 11 years on Tuesday, outlining plans to respond to global…

#Celltrion chairman Seo Jung-jin returned to lead the shareholder meeting after 11 years, outlining expansion plans, investment strategy and outlook amid global uncertainty.

Read more: buff.ly/ayMYb6R

#Korea #Biotech #Pharma

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Celltrion Launches AVTOZMA® Subcutaneous Formulation for U.S. Patients Celltrion has officially launched the AVTOZMA® (tocilizumab-anoh) subcutaneous formulation in the U.S., offering new treatment options for chronic inflammatory diseases.

Celltrion Launches AVTOZMA® Subcutaneous Formulation for U.S. Patients #United_States #Incheon #Celltrion #AVTOZMA #tocilizumab-anoh

IT Chosun

@itchosun.bsky.social

2 months ago

Next-Generation Leaders of K-Bio Put to the Test at JPMorgan As owner heirs of major Korean biotech companies took center stage at the JPMorgan Healthcare Conference (JPMHC)—the world’s largest pharmaceutical and biotech

According to industry sources, owner successors of leading Korean biotech firms drew significant attention as they stepped forward at the 44th JPMorgan Healthcare Conference held recently in San Francisco.
#JPMorgan #JPMHC #Celltrion #Lotte #SK #bio #it #itchosun #chosun #SouthKorea #Korea

Thiard News@F4F

@newsen.bsky.social

2 months ago

Celltrion Showcases Innovative Drug Development Strategies at J.P. Morgan Healthcare Conference At the J.P. Morgan Healthcare Conference, Celltrion outlines a robust roadmap for drug development, expanding U.S. manufacturing and R&D capabilities, signaling its commitment to innovation.

Celltrion Showcases Innovative Drug Development Strategies at J.P. Morgan Healthcare Conference #South_Korea #Drug_Development #Biopharmaceutical #Incheon #Celltrion

Thiard News@F4F

@newsen.bsky.social

2 months ago

Celltrion to Showcase Innovations at 44th J.P. Morgan Healthcare Conference in San Francisco Celltrion, Inc. announces its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference with key executives taking the stage.

Celltrion to Showcase Innovations at 44th J.P. Morgan Healthcare Conference in San Francisco #South_Korea #Healthcare_Conference #J.P._Morgan #Incheon #Celltrion

Thiard News@F4F

@newsen.bsky.social

4 months ago

Celltrion Receives FDA Approval for 300mg OMLYCLO® Offering Patients Enhanced Treatment Options Celltrion's OMLYCLO® (omalizumab-igec) has been approved by the FDA in a new 300mg strength, providing patients with more flexible treatment options.

Celltrion Receives FDA Approval for 300mg OMLYCLO® Offering Patients Enhanced Treatment Options #South_Korea #Incheon #Celltrion #OMLYCLO #XOLAIR

Thiard News@F4F

@newsen.bsky.social

4 months ago

Celltrion's ZYMFENTRA® Shows Efficacy in Diverse Crohn's Disease Cases: New Insights from LIBERTY-CD Analysis Celltrion reveals compelling results from the LIBERTY-CD post-hoc analysis, demonstrating ZYMFENTRA's consistent efficacy across Crohn's disease sites. Read more!

Celltrion's ZYMFENTRA® Shows Efficacy in Diverse Crohn's Disease Cases: New Insights from LIBERTY-CD Analysis #South_Korea #Crohn's_Disease #Incheon #Celltrion #ZYMFENTRA

Thiard News@F4F

@newsen.bsky.social

5 months ago

Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders Kaigene has signed a licensing deal with Celltrion to develop advanced antibody therapeutics targeting autoimmune diseases, opening new avenues for treatment.

Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders #United_States #Rockville #Celltrion #antibody_therapeutics #Kaigene

Thiard News@F4F

@newsen.bsky.social

5 months ago

U.S. FDA Designates Celltrion's Biosimilars STOBOCLO and OSENVELT as Interchangeable Choices The FDA has granted Celltrion's biosimilars, STOBOCLO and OSENVELT, interchangeability designations, improving treatment options for osteoporosis and cancer-related bone conditions.

U.S. FDA Designates Celltrion's Biosimilars STOBOCLO and OSENVELT as Interchangeable Choices #USA #Incheon #Celltrion #STOBOCLO #OSENVELT

Thiard News@F4F

@newsen.bsky.social

5 months ago

WellsCare and Celltrion Canada Join Forces to Revolutionize Pain Management Technology WellsCare partners with Celltrion Canada to launch innovative pain relief technology across North America, enhancing patient care.

WellsCare and Celltrion Canada Join Forces to Revolutionize Pain Management Technology #South_Korea #Seoul #Celltrion #WellsCare #IASO

Thiard News@F4F

@newsen.bsky.social

5 months ago

FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions The FDA has approved YUFLYMA® and its unbranded counterpart for new pediatric uses, enhancing treatment options for chronic inflammatory diseases in kids.

FDA Expands Pediatric Use of YUFLYMA® and Unbranded Adalimumab-aaty for Chronic Conditions #United_States #Incheon #Celltrion #YUFLYMA® #Adalimumab

Thiard News@F4F

@newsen.bsky.social

5 months ago

Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment Celltrion proudly announces the FDA's approval of EYDENZELT®, a biosimilar to EYLEA®, enhancing treatment options for retinal diseases like AMD and DME.

Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment #South_Korea #FDA_Approval #Incheon #Celltrion #EYDENZELT

Thiard News@F4F

@newsen.bsky.social

6 months ago

Celltrion's AVTOZMA®: A New Era for IV Treatments in the US Market Celltrion has launched AVTOZMA®, an intravenous formulation of tocilizumab-anoh, approved for treating various immunological conditions, expanding options for patients and physicians.

Celltrion's AVTOZMA®: A New Era for IV Treatments in the US Market #United_States #Incheon #Celltrion #AVTOZMA® #Tocilizumab

Thiard News@F4F

@newsen.bsky.social

7 months ago

FDA Approves AVTOZMA® for Expanded Treatment of Cytokine Release Syndrome The FDA has granted approval for AVTOZMA® intravenous formulation, expanding its indications to treat cytokine release syndrome in both adults and children.

FDA Approves AVTOZMA® for Expanded Treatment of Cytokine Release Syndrome #Celltrion #AVTOZMA® #Cytokine_Release_Syndrome

Profit Trading USA

@profittradingusa.bsky.social

8 months ago

South Korea’s Celltrion says tapped to buy US pharma factory to offset tariff risk SEOUL (Reuters) -South Korean pharmaceutical firm Celltrion said on Tuesday that in an attempt to offset the risk of U.S. tariffs it had become the preferred bidder to acquire a U.S. manufacturing factory from an unnamed global pharmaceutical company. Celltrion’s Founder and Chief Executive Seo Jung-jin told a briefing it planned to invest 700 billion won ($503.78 million) in the acquisition and operation of the factory, without giving a breakdown of the figure. The company could make an additional investment ranging from 300 billion won to 700 billion won depending on U.S. tariff policy. The U.S. has been conducting a national security investigation into the pharmaceutical sector and President Donald Trump said earlier this month that pharmaceutical tariffs could be as high as 200%. Celltrion said it would not disclose further details, including the name of the seller and its location, until the signing of the final agreement, which is expected in early October.

Click Subscribe #Celltrion #Pharmaceuticals #TariffRisk #USManufacturing #SouthKorea

Thiard News@F4F

@newsen.bsky.social

8 months ago

Celltrion USA Launches New Denosumab Biosimilars: STOBOCLO® and OSENVELT® Celltrion USA has announced the commercial launch of two denosumab biosimilars, STOBOCLO® and OSENVELT®, boosting treatment options in the U.S.

Celltrion USA Launches New Denosumab Biosimilars: STOBOCLO® and OSENVELT® #USA #Jersey_City #Celltrion #STOBOCLO #OSENVELT

Thiard News@F4F

@newsen.bsky.social

9 months ago

Celltrion Expands Pediatric Options with New STEQEYMA® Presentation Approval Celltrion has received FDA approval for a new STEQEYMA® presentation, offering flexible dosing for pediatric patients with psoriasis and arthritis.

Celltrion Expands Pediatric Options with New STEQEYMA® Presentation Approval #South_Korea #FDAApproval #Incheon #Celltrion #STEQEYMA

Thiard News@F4F

@newsen.bsky.social

10 months ago

Celltrion's YUFLYMA® Secures Full FDA Interchangeability for All Dosage Forms Celltrion announces FDA's expanded interchangeability designation for YUFLYMA® (adalimumab-aaty), a key development in biosimilar medications.

Celltrion's YUFLYMA® Secures Full FDA Interchangeability for All Dosage Forms #South_Korea #Incheon #Celltrion #Humira #YUFLYMA

Thiard News@F4F

@newsen.bsky.social

10 months ago

Celltrion's YUFLYMA® Receives Expanded FDA Interchangeability Designation Celltrion, Inc. proudly announces that its biosimilar YUFLYMA® has received expanded FDA interchangeability designation for all its dosage forms, improving patient access.

Celltrion's YUFLYMA® Receives Expanded FDA Interchangeability Designation #None #Celltrion #Humira #YUFLYMA

Thiard News@F4F

@newsen.bsky.social

11 months ago

Celltrion Unveils Six Abstracts on IBD at 2025 Digestive Disease Week, Enhancing Clinical Insights At the 2025 DDW in San Diego, Celltrion will present six studies on IBD, focusing on ZYMFENTRA's effectiveness for Crohn's and ulcerative colitis.

Celltrion Unveils Six Abstracts on IBD at 2025 Digestive Disease Week, Enhancing Clinical Insights #South_Korea #Inflammatory_Bowel_Disease #Incheon #Celltrion #ZYMFENTRA

Thiard News@F4F

@newsen.bsky.social

11 months ago

Celltrion's YUFLYMA® Receives FDA's Interchangeable Designation to Humira® Celltrion’s YUFLYMA® has been recognized by the FDA as an interchangeable biosimilar to Humira®, enhancing access for patients across various treatment needs.

Celltrion's YUFLYMA® Receives FDA's Interchangeable Designation to Humira® #USA #Incheon #Celltrion #Humira #YUFLYMA

Thiard News@F4F

@newsen.bsky.social

1 year ago

Celltrion's STEQEYMA® Introduced to Costco Member Prescription Program Celltrion's biosimilar STEQEYMA® (ustekinumab-stba) is set to improve treatment access for various inflammatory conditions through Costco's prescription program.

Celltrion's STEQEYMA® Introduced to Costco Member Prescription Program #USA #Jersey_City #Celltrion #Stelara® #STEQEYMA®

Thiard News@F4F

@newsen.bsky.social

1 year ago

Celltrion's OMLYCLO® Approved as First Interchangeable Biosimilar to XOLAIR® The U.S. FDA has approved Celltrion's OMLYCLO®, the first interchangeable biosimilar to XOLAIR®, enhancing access for asthma and allergy patients.

Celltrion's OMLYCLO® Approved as First Interchangeable Biosimilar to XOLAIR® #United_States #Jersey_City #Celltrion #OMLYCLO #XOLAIR

YesPunjab.com

@handle.invalid

1 year ago

Celltrion's bone disease biosimilars get approval in US - Yes Punjab News Celltrion, a South Korean biopharmaceutical firm, received FDA approval for two new biosimilars, Stoboclo and Osenvelt, for bone disease treatment in the U.S. The company aims to expand its biosimilar...

Celltrion's bone disease biosimilars get approval in US
yespunjab.com?p=99313

#Celltrion #Biosimilars #BoneDisease #USApproval #PharmaNews #Healthcare #Biologics #MedicalBreakthrough #FDAApproval #Biotech #RheumatoidArthritis #Osteoporosis

Thiard News@F4F

@newsen.bsky.social

1 year ago

Celltrion Gains FDA Approval for Two New Biosimilars, STOBOCLO® and OSENVELT® Celltrion has successfully obtained FDA approval for its two new biosimilars, STOBOCLO® and OSENVELT®, enhancing treatment options for patients with osteoporosis and bone-related cancer issues.

Celltrion Gains FDA Approval for Two New Biosimilars, STOBOCLO® and OSENVELT® #Jersey_City #Celltrion #STOBOCLO #OSENVELT

KStrategy&

@kstrategyand.bsky.social

1 year ago

Weekly Roundup - PHARMA - 10 February 2025 🔊Celltrion’s Avtozma Wins FDA Approval for Autoimmune & Inflammatory Diseases Avtozma, an Actemra biosimilar, is approved in both IV and SC forms, backed by a Phase III trial confirming its similarity...

Weekly Roundup - PHARMA - 10 February 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#Celltrion #Avtozma #Axsome #Symbravo #Anzupgo #PharmaNews #Biotech #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec #KStrategyand

Thiard News@F4F

@newsen.bsky.social

1 year ago

FDA Greenlights Celltrion’s AVTOZMA®, A Biosimilar to ACTEMRA® for Multiple Conditions Celltrion's AVTOZMA® has received FDA approval as a biosimilar to ACTEMRA®, expanding treatment options for various conditions including rheumatoid arthritis.

FDA Greenlights Celltrion’s AVTOZMA®, A Biosimilar to ACTEMRA® for Multiple Conditions #USA #FDA #Jersey_City #Celltrion #AVTOZMA

YesPunjab.com

@handle.invalid

1 year ago

Celltrion's autoimmune disease treatment hits 5 major European countries - Yes Punjab News Celltrion launches its autoimmune disease treatment SteQeyma in five major European countries, following European Commission approval. The company aims for significant growth with expanded sales and a...

Celltrion's autoimmune disease treatment hits 5 major European countries
yespunjab.com?p=85477

#Celltrion #AutoimmuneTreatment #SteQeyma #EuropeanLaunch #HealthNews #Biosimilars #ChronicDiseases #Gastroenterology #Dermatology #Rheumatology

The Korea Herald 코리아헤럴드

@thekoreaherald.bsky.social

1 year ago

[JPM 2025] Celltrion highlights breakthrough therapies, unveils ambitious clinical plans by 2028 SAN FRANCISCO -- Celltrion unveiled a detailed road map for its innovative drug pipeline to global investors and expressed commitment to becoming a leading global player in innovative pharmaceuticals,...

South Korean biopharmaceuticals giant Celltrion has big plans for 2025.

Find out more:
www.koreaherald.com/article/1039...

#Celltrion #JPM2025

Korea JoongAng Daily

@koreajoongangdaily.com

1 year ago

Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its broader strategy to expand into the original drug market.

#Celltrion, a Korean biotech company known for its biosimilars, plans to generate 20 percent of its annual revenue this year from its original drug #Zymfentra as part of its broader strategy to expand into the original drug market.